This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MD Gains 11% Since Q4 Earnings Release, Unveils '25 View
by Zacks Equity Research
Pediatrix Medical's fourth-quarter results reflect a declining overall expense level. It estimates 2025 net income to lie within $98.3-$112.9 million.
Should Value Investors Buy Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Healthcare Stocks to Buy as the Sector Stages a Comeback
by Abhinab Dasgupta
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the incoming Trump administration's healthcare policies.
Tenet Q4 Earnings Beat Estimates on Favorable Payer Mix
by Zacks Equity Research
THC expects net operating revenues between $20.6 billion and $21 billion in 2025.
Compared to Estimates, Tenet (THC) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Tenet (THC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tenet Healthcare (THC) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 17.41% and 1.75%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Can Tenet Healthcare Navigate Through Lower Revenues in Q4?
by Zacks Equity Research
THC's fourth-quarter results are likely to reflect growing patient admissions, utilization and patient days.
Wall Street Analysts See Tenet (THC) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Tenet (THC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Countdown to Tenet (THC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Tenet (THC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Tenet Healthcare (THC) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Tenet Healthcare (THC) closed the most recent trading day at $143.71, moving -0.64% from the previous trading session.
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health, Acadia Healthcare and Community Health have been highlighted in this Industry Outlook article.
Thriving in Healthcare: 5 Hospital Stocks to Keep on Your Radar
by Kaibalya Pravo Dey
The Zacks Medical-Hospital industry is likely to benefit from improving financial, operating and staffing stability. Companies like HCA, THC, UHS, ACHC and CYH are well-positioned to gain from these trends.
Tenet Healthcare Corporation (THC) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Tenet (THC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tenet Healthcare (THC) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
The latest trading day saw Tenet Healthcare (THC) settling at $139.67, representing a +0.56% change from its previous close.
Here's Why Tenet Healthcare (THC) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Tenet Healthcare (THC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tenet Healthcare (THC) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Tenet Healthcare (THC) concluded the recent trading session at $134.42, signifying a -0.01% move from its prior day's close.
Should You Invest in Tenet (THC) Based on Bullish Wall Street Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Tenet Healthcare Corporation (THC) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Tenet (THC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
4 Sector ETFs & Stocks to Benefit Despite Cooling Inflation
by Sanghamitra Saha
These sector ETFs and stocks may win amid cooling inflation.
Tenet Healthcare (THC) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Tenet Healthcare (THC) closed at $127.63, indicating a -1.27% shift from the previous trading day.
Why Tenet (THC) Could Beat Earnings Estimates Again
by Zacks Equity Research
Tenet (THC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Community Health Drops 16.4% in 6 Months: Should You Hold or Fold?
by Zacks Equity Research
CYH's declining volumes and industry pressures raise concerns about its outlook despite efforts like strategic divestitures
Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.